

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ASCENTAGE PHARMA GROUP INTERNATIONAL**

**亞盛醫藥集團**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6855)**

### **CLARIFICATION ANNOUNCEMENT IN RELATION TO GRANT OF AWARDS UNDER THE RSU SCHEME**

References are made to (i) the prospectus of Ascentage Pharma Group International (the “**Company**”) dated October 16, 2019 (the “**Prospectus**”); (ii) the 2019 annual report of the Company dated March 29, 2020; (iii) the 2020 interim report of the Company dated August 18, 2020 in relation to, among other things, the RSU Scheme of the Company; and (iv) the announcement of the Company dated September 16, 2020 in relation to the grant of awards under the RSU Scheme of the Company (the “**Announcement**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Prospectus and the Announcement.

Due to an inadvertent error in the calculation of (i) the number of RSU Selected Persons who were to be granted RSUs under the RSU Scheme on September 14, 2020; and (ii) the number of RSUs of the Company which were to be granted under the RSU Scheme on September 14, 2020, the Company wishes to clarify that the second paragraph on page 1 of the Announcement should read as follows (with the correction underlined for ease of reference):

“The Board hereby announces that, on September 14, 2020, the Company granted 2,590,592 RSUs under the RSU Scheme (the “**Awards**”), representing 2,590,592 Shares to 50 RSU Selected Persons, who are employees of the Group. Shares representing the maximum number of RSUs of the Company that may be granted under the RSU Scheme (being 5,274,657 Shares) were issued and allotted to the RSU Holdco as the settlor of the RSU Scheme prior to the Listing. The vesting of the Awards will be satisfied by such Shares held by the RSU Holdco.”

Save for the aforesaid, all the information in the Announcement remains true and accurate.

By order of the Board  
**Ascentage Pharma Group International**  
**Dr. Yang Dajun**  
*Chairman and Executive Director*

Suzhou, the PRC, March 19, 2021

*As at the date of this announcement, the Board comprises Dr. Yang Dajun as chairman and executive Director, Dr. Wang Shaomeng, Dr. Tian Yuan, Mr. Zhao Qun, Dr. Lu Simon Dazhong and Mr. Liu Qian as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng and Mr. Ren Wei as independent non-executive Directors.*